Tolnaftate
CAS 2398-96-1
Tolnaftate (CAS 2398-96-1) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 105 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| NATURAL CURES FUNGAL NAIL Patches | TOLNAFTATE 06KB629TKV |
TOLNAFTATE | 20260504 |
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 17121.4452 nM | 75 | - |
| - | Potency | 20649.3641025641 nM | 32 | - |
| - | IC50 | 34625.35538461538 nM | 12 | - |
| - | EC50 | 0.3 ug.mL-1 | 1 | - |
| - | Ki | 1277 nM | 1 | - |
| 5-hydroxytryptamine receptor 2B GPCR |
Ki | 5.894 | - | Homo sapiens |
| Cytochrome P450 2C19 Enzyme |
IC50 | 5.523 | - | Homo sapiens |
| Lanosterol 14-alpha demethylase Enzyme |
IC50 | 4.3 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Blood uric acid decreased | 6 | 31.661 | 10005860 |
| Blood creatinine decreased | 8 | 29.422 | 10005482 |
| Paraproteinaemia | 5 | 28.838 | 10061333 |
| Cancer pain | 7 | 27.605 | 10058019 |
| Hypertrophy | 5 | 27.009 | 10020880 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TOLNAFTATE | 10637 | SU | MTHSPL |
| Tolnaftate | 10637 | SU | MTHSPL |
| tolnaftate | 10637 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tolnaftate used for in pharmaceutical contexts?
Tolnaftate (CAS 2398-96-1) appears in DailyMed active-ingredient label rows, including NATURAL CURES FUNGAL NAIL Patches.
What are the known adverse events for Tolnaftate?
Tolnaftate has 105 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Blood uric acid decreased, Blood creatinine decreased, Paraproteinaemia, Cancer pain, Hypertrophy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tolnaftate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Tolnaftate with EU status "permitted".
What clinical phase is Tolnaftate in?
Tolnaftate is rendered with ChEMBL max phase 3.
What bioactivity targets are documented for Tolnaftate?
Tolnaftate has 8 bioactivity rows in this page query. Rendered target entries include 5-hydroxytryptamine receptor 2B, Cytochrome P450 2C19, Lanosterol 14-alpha demethylase.